Authors

Tycel J. Phillips, MD, MPH, is an associate professor in the Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, at City of Hope.

Latest:

Dr Phillips on Future Avenues for Improving the Management of High-Risk MCL

Tycel J. Phillips, MD, MPH, discusses the need for more large, randomized clinical trials enrolling patients with high-risk MCL.

Tycel Jovelle Phillips, MD, University of Michigan

Latest:

Dr. Phillips on the Current Role of Ibrutinib in MCL

Tycel Jovelle Phillips, MD, discusses the current role of ibrutinib in mantle cell lymphoma.

Tyler Greer

Latest:

Sleckman to lead O'Neal Comprehensive Cancer Center

Barry Paul Sleckman, MD, PhD, has been named director of the O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham.

UC San Diego Health

UCS

Udai Banerji, MD

Latest:

Dr. Banerji on the Clinical Activity of VS-6766/Defactinib in KRAS-Mutant Tumors

Udai Banerji, MD, discusses the results from a phase 1 trial with the combination of VS-6766 (CH5126766) and defactinib in KRAS-mutant tumors.

Udit Verma, MD

Latest:

Dr. Udit Verma on Managing Regorafenib Side Effects in CRC

Ulka Vaishampayan, MD

Latest:

Triple Combination Therapies in RCC: Clinical Trial Insights

Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.

Ulka Vaishampayan, MD, Barbara Ann Karmanos Cancer Institute

Ulka Vaishampayan, MD, Wayne State University Karmanos Cancer Institute

Ulrik Lassen, MD, PhD

Latest:

Dr. Lassen Discusses TRK Fusions in Pediatric Patients

Ulrik Lassen, MD, PhD, head of the Phase I Unit at Rigshospitalet, discusses TRK fusions in pediatric patients with cancer.

Umamaheswar Duvvuri, MD, PhD

Latest:

Dr. Umamaheswar Duvvuri on Impact of Multiple Genetic Mutations in Advanced Thyroid Cancer

Umamaheswar Duvvuri, MD, PhD, Assistant Professor of Otolaryngology (ENT) at the University of Pittsburgh Medical Center, talks about potential genetic signatures for locally advanced, well differentiated thyroid cancers.

Umberto Capitanio, MD

Latest:

Dr. Capitanio Discusses Adjuvant Therapy for High-Risk Kidney Cancer

Umberto Capitanio, MD, FEBU, department of Urology, San Raffaele Scientific Institute, University Vita-Salute San Raffaele, discusses adjuvant therapy for patients with high-risk kidney cancer without metastases.

Umberto Malapelle, PhD

Latest:

Unanswered Questions With the Role of TMB in NSCLC

Umberto Malapelle, PhD, assistant professor, University of Naples Federico II, discusses unanswered questions regarding the role of tumor mutational burden in non–small cell lung cancer.

Umesh Mahantshetty, MD, MBBS

Latest:

Dr. Mahantshetty on Challenges With Concomitant Chemoradiation Trial in Cervical Cancer

Umesh Mahantshetty, MD, MBBS, radiation oncologist, Tata Memorial Hospital, Mumbai, discusses challenges with a trial (NCT00193791) conducted by Tata Memorial Hospital seeking to solidify the impact of concomitant chemoradiation with FIGO stage IIIb squamous cervical cancer.

University of Hamburg

Ursula A. Matulonis, MD

Ursula A. Matulonis, MD, is chief of the Division of Gynecologic Oncology and the Brock-Wilcon Family Chair at the Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School, both in Boston, Massachusetts.

Latest:

Gynecologic Oncology Surgery Advances Are Propelled by Minimally Invasive Techniques: With Ursula Matulonis, MD; and Taymaa May, MD, MSc

In the inaugural episode of this new podcast series, Drs Matulonis and May discuss advances in gynecologic cancer surgery.

Ursula A. Matulonis, MD, Dana-Farber Cancer Institute

Ursula A. Matulonis, MD, Harvard Medical School